KFAS
ANIP icon

Keating Financial Advisory Services’s ANI Pharmaceuticals ANIP Stock Holding History

Keating Financial Advisory Services’s Portfolio ANIP Stock Details ANIP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.24K Buy
15
+1
+7% +$80 ﹤0.01% 2100
2026
Q1 		$1.08K Buy
+14
New +$1.09K ﹤0.01% 2064

Other funds holding ANIP

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return
Arrowstreet Capital
Arrowstreet Capital Boston, Massachusetts $225B AUM 49.49% 1-Year Est. Return
GACM
Global Alpha Capital Management Montreal, Quebec, Canada $1.67B AUM 35.09% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Keating Financial Advisory Services's ANIP Position: Q2 2026 in Review

Keating Financial Advisory Services increased its ANI Pharmaceuticals (ANIP) stake by 7.1% in Q2 2026, buying an estimated $80 and bringing the position to 15 shares worth $1.24K. The position accounts for ﹤0.01% of the portfolio, ranked #2100.

Keating Financial Advisory Services first reported a position in ANIP in Q1 2026 and has held it in 2 quarters since. 307 funds tracked by Wall St. Rank hold ANIP as of Q2 2026.

  • Keating Financial Advisory Services held 15 shares of ANI Pharmaceuticals worth $1.24K as of Q2 2026.
  • Keating Financial Advisory Services bought 1 ANI Pharmaceuticals share in Q2 2026, an estimated $80.
  • ANI Pharmaceuticals made up ﹤0.01% of Keating Financial Advisory Services's portfolio in Q2 2026, its #2100 holding.
  • Keating Financial Advisory Services first reported a position in ANI Pharmaceuticals in Q1 2026 and has held it in 2 quarters since.
  • 307 funds tracked by Wall St. Rank held ANI Pharmaceuticals as of Q2 2026.

Based on Keating Financial Advisory Services's 13F filing for Q2 2026, filed 11 Aug 2026.